Browsing by Author "Carles Galceran, Joan"
Now showing items 1-18 of 18
-
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Carles Galceran, Joan; Chowdhury, Simon; McGregor, Bradley; Merseburger, Axel; Agarwal, Neeraj; Azad, Arun (Future Medicine, 2022-03) -
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Neeb, Antje; Herranz Martín, Nicolás; Arce Gallego, Sara; Buroni, Lorenzo; Yuan, Wei; Athie Cuervo, Alejandro; Casals, Teresa; Casanova Salas, Irene; Cordoba, Sarai; Castro, Natalia; González Rodríguez, Macarena; Morales Barrera, Rafael; Suárez Rodríguez, Cristina; Carles Galceran, Joan; Serra Elizalde, Violeta; Mateo Valderrama, Joaquim; Miranda, Susana (Elsevier, 2021-02) -
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
Carles Galceran, Joan; Pichler, Angelika; Korunkova, Hana; Tomova, Antoaneta; Ghosn, Marwan; El Karak, Fadi (Wiley, 2019-03-01) -
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
de Wit, R.; Wülfing, C.; Castellano, D.; Kramer, G.; Eymard, J.-C.; Sternberg, C. N.; Carles Galceran, Joan (Elsevier, 2021-10) -
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Jiménez, Natalia; Reig, Òscar; Montalbo, Ruth; Milà-Guasch, Maria; Nadal-Dieste, Lluis; Castellano, Giancarlo; Carles Galceran, Joan; Suárez Rodríguez, Cristina (Frontiers Media, 2020-11-02) -
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
Serrano Garcia, César; Vivancos Prellezo, Ana; Lopez Pousa, Antonio; Matito Ariza, Judit; Mancuso, Francesco Mattia; Valverde Morales, Claudia Maria; Quiroga Gómez, Sergi; Dopazo Taboada, Cristina; Sanso Martinez, Miriam; Garcia Valverde, Luis Alfonso; Rosell Aluja, Jordi; Carles Galceran, Joan; Arribas López, Joaquin Vicente; Castro Boix, Sandra; Landolfi, Stefania (BMC, 2020-02-05) -
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
Malik, Zafar; Di Lorenzo, Giuseppe; Pichler, Angelika; De Giorgi, Ugo; Hitier, Simon; Ecstein-Fraisse, Evelyne; Carles Galceran, Joan (MDPI, 2020-04-17) -
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
Wilson, Brooke; Armstrong, Andrew J.; Sternberg, C. N.; Ryan, Charles; Scher, Howard I.; Carles Galceran, Joan; de Bono, Johann S (Elsevier, 2022-07) -
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
Garralda Cabanas, Elena; Aguilar, Susana; Sala De Vedruna, Gemma; Viaplana Donato, Cristina; González-Zorelle, Jenifer; Grazia LoGiacco, Deborah; Ogbah, Zighereda; Mancuso, Francesco Mattia; Fasani, Roberta; Jiménez Flores, José Antonio; Martinez, Paola; Oaknin Benzaquen, Ana Mazaltob; Antunes de Melo Oliveira, Ana Mafalda; Balmaña Gelpí, Judith; Carles Galceran, Joan; Macarulla Mercadé, Teresa; Elez Fernandez, Mª Elena; Alsina Maqueda, Maria; Braña Garcia, Irene; Felip Font, Enriqueta; Tabernero Caturla, Josep; Rodon Ahnert, Jordi; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Ramos Masdeu, Laia; Saura Manich, Cristina; Ruiz Pace, Fiorella; Dienstmann, Rodrigo (American Society of Clinical Oncology, 2020-05-14) -
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
Sabaté Gallego, Mònica; Pérez Esquirol, Eulalia; García Doladé, Núria; Vidal Guitart, Xavier; Farriols Danes, Anna Maria; Felip Font, Enriqueta; Braña Garcia, Irene; Carles Galceran, Joan; Morales Barrera, Rafael; Agustí Escasany, Maria Antònia; Carreras Soler, Maria Josep; Muñoz Couselo, Eva (Frontiers Media, 2022-08-22) -
Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits
Moserle, Lidia; Pons, Roser; Martínez-Lozano, Mar; Jiménez-Valerio, Gabriela A; Vidal, August; Suárez Rodríguez, Cristina; Trilla Herrera, Enric; Jiménez Flores, José Antonio; Torres Ramirez, Inés de; Carles Galceran, Joan (Wiley, 2020-12-07) -
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Yu, Evan; Piulats, Josep M.; Gravis, Gwenaelle; Fong, Peter C.C.; Todenhöfer, Tilman; Laguerre, Brigitte; Carles Galceran, Joan (Elsevier, 2023-01) -
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
Matos Garcia, Ignacio; Hierro Carbó, Cinta; Martín Liberal, Juan Jesús; Berche, Roger; Pedrola Gómez, Anna; Braña Garcia, Irene; Azaro Pedrazzoli, Analía Beatriz; Vieito Villar, Maria; Saavedra Gadea, Omar; Gardeazabal, Itziar; Hernando Calvo, Alberto; Alonso-Casal, Guzman; Galvao De Aquiar, Vladimir; Ochoa de Olza Amat, Maria; Ros Montañá, Fco. Javier; Viaplana Donato, Cristina; Elez Fernandez, Mª Elena; Rodon Ahnert, Jordi; Macarulla Mercadé, Teresa; Oaknin Benzaquen, Ana Mazaltob; Carles Galceran, Joan; Felip Font, Enriqueta; Tabernero Caturla, Josep; Garralda Cabanas, Elena; Villacampa Javierre, Guillermo; Saura Manich, Cristina; Muñoz Couselo, Eva; Dienstmann, Rodrigo (Elsevier, 2021-09) -
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
Gulley, James L.; Borre, Michael; Vogelzang, Nicholas J.; Ng, Siobhan; Parker, Chris C.; Carles Galceran, Joan; Agarwal, Neeraj (American Society of Clinical Oncology, 2019-05-01) -
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Carles Galceran, Joan; Fay, Andre P; Shore, Neal; Agarwal, Neeraj; Azad, Arun; Dunshee, Curtis (Future Science Group, 2022-09) -
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial
Carles Galceran, Joan; Mellado, Begoña; Méndez-Vidal, María J.; Vázquez, Sergio; Gonzalez-del-Alba, Aranzazu; Morales Barrera, Rafael; Alonso-Gordoa, Teresa (Elsevier, 2022-09) -
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Heidenreich, Axel; Gillessen, Silke; Heinrich, Daniel; Keizman, Daniel; O'Sullivan, Joe M; Carles Galceran, Joan (BMC, 2019-01-07) -
Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease
Suárez Rodríguez, Cristina; Marmolejo Castañeda, David; Valdivia Bustamante, Augusto Alejandro; Morales Barrera, Rafael; González Rodríguez, Macarena; Mateo Valderrama, Joaquim; Semidey Raven, Maria Eugenia; Lorente García, David; Trilla Herrera, Enric; Carles Galceran, Joan (Frontiers Media, 2022-10-04)